Why Axon's 50% Drawdown Is a Risk Event to Watch

Axon's 50% Decline: The Valuation Mechanism

Axon (AXON) has lost more than half its market value since October 2025, sliding from a high of $886 to roughly $390. That drawdown occurred while the company maintained revenue growth above 30%. The combination of accelerating sales and a collapsing share price points to a valuation-driven selloff, not a fundamental deterioration. The sector-wide rotation against high-growth software names – the so-called SaaSpocalypse – has hit Axon harder than many peers because its premium multiple left little room for error on interest rates or sentiment.

Understanding the mechanism is straightforward. When the market reprices the entire growth basket downward, stocks with elevated price-to-sales ratios compress fastest. Axon's forward revenue multiple peaked near 20x in late 2025. As the rotation accelerated, that multiple contracted by roughly 60%, more than offsetting the 30% revenue expansion. The result was a share price cut in half even as underlying business metrics improved. This is not a warning about Axon's execution; it is a reflection of how liquidity and sector positioning drive short-term outcomes. Traders watching similar patterns in other names, such as the Nebius 103% rally reversal covered in market analysis, should recognize the same multiple-compression risk when growth narratives shift.

The Revenue Visibility vs. Macro Risk Tradeoff

The disconnect between Axon's operational performance and its stock price defines the risk event for holders. The company continues to win contracts with law enforcement agencies, and its recurring revenue base has expanded. Yet the market is pricing those future cash flows as if a recession or a structural slowdown in public safety spending were imminent. That gap creates two possible outcomes: either the valuation eventually re-anchors to the growth trajectory, or the growth itself decelerates enough to justify the new lower multiple.

For traders deciding whether to hold or add, the key variable is the timeline of a potential recovery. Axon's customer base – largely government entities with multi-year budgeting cycles – provides revenue visibility that many enterprise SaaS companies lack. That characteristic could shorten the duration of the selloff if macro fears ease. Conversely, the same feature means that any weakness in state or federal budgets would hit Axon with a lag, making the current price a leading indicator rather than a reaction to known data. As part of broader stock market analysis, the rotation into value and away from high-growth names shows no sign of reversing until rate expectations stabilize. Some analysts have flagged Meta and ServiceNow as undervalued, raising the question of whether Axon will follow a similar re-rating once the sector rotation exhausts itself (SA Analysts Flag Meta, ServiceNow as Undervalued Tech).

What Would Validate a Reversal at $390

For the risk profile to improve, two conditions need to materialize. First, the revenue guidance must not only hold but accelerate, proving that the 30% growth rate is sustainable. Second, the interest rate outlook must stop moving against growth stocks. A clear catalyst would be a quarterly report that shows margins expanding faster than consensus expects, because that would allow the stock to earn a higher multiple without requiring a sector rotation. Conversely, a downgrade from a major sell-side firm or a government contract delay would deepen the drawdown.

The setup now is binary. Axon either stabilizes around current levels and begins a gradual re-rating as SaaSpocalypse fatigue sets in, or it breaks below $350, which could trigger stop-loss selling from momentum funds that piled in during the 2025 rally. The next earnings release, expected within weeks, will be the first real test. Until then, the stock remains a high-conviction watchlist item for traders who can withstand continued volatility.